Pepinemab

Evidence outlook · lead readout

NCT04381468 · Alzheimer Disease

The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.

NCT04381468: The study randomized 50 participants to pepinemab or placebo and masked participants, care providers, investigators, and outcome assessors. The primary endpoint was a clinical safety measure, but results for the comparison have not been posted, and the relatively small sample limits the strength of the evidence.